BSE Live
Mar 27, 16:01Prev. Close
165.35
Open Price
163.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:56Prev. Close
165.20
Open Price
164.05
Bid Price (Qty.)
163.08 (14946)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Marksans Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 1.64 | 1.44 | 1.03 | -4.92 | -5.92 | |
| Diluted EPS (Rs.) | 1.64 | 1.44 | 1.03 | -4.70 | -5.92 | |
| Cash EPS (Rs.) | 1.86 | 1.67 | 1.25 | -4.43 | -5.52 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 8.45 | 3.80 | 2.50 | -5.48 | -1.51 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 8.45 | 3.80 | 2.50 | -5.48 | -1.51 | |
| Dividend / Share(Rs.) | 0.12 | 0.10 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 9.91 | 8.17 | 4.99 | 4.20 | 4.21 | |
| PBDIT/Share (Rs.) | 2.90 | 2.26 | 1.26 | -3.15 | -2.14 | |
| PBIT/Share (Rs.) | 2.68 | 2.04 | 1.03 | -3.64 | -2.54 | |
| PBT/Share (Rs.) | 2.36 | 1.64 | 0.77 | -4.97 | -3.61 | |
| Net Profit/Share (Rs.) | 1.64 | 1.44 | 1.03 | -4.92 | -5.92 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 29.29 | 27.66 | 25.19 | -74.92 | -50.97 | |
| PBIT Margin (%) | 27.07 | 24.91 | 20.66 | -86.56 | -60.43 | |
| PBT Margin (%) | 23.83 | 20.08 | 15.39 | -118.31 | -85.79 | |
| Net Profit Margin (%) | 16.54 | 17.64 | 20.58 | -117.12 | -140.78 | |
| Return on Networth / Equity (%) | 19.41 | 37.94 | 41.02 | 0.00 | 0.00 | |
| Return on Capital Employed (%) | 18.70 | 30.59 | 32.96 | 83.48 | 1,144.05 | |
| Return on Assets (%) | 12.73 | 14.75 | 12.75 | -73.62 | -53.54 | |
| Total Debt/Equity (X) | 0.13 | 0.53 | 0.86 | -0.46 | -1.86 | |
| Asset Turnover Ratio (%) | 76.94 | 83.66 | 61.98 | 62.86 | 38.03 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.19 | 1.23 | 0.89 | 0.35 | 0.36 | |
| Quick Ratio (X) | 1.89 | 0.95 | 0.62 | 0.25 | 0.27 | |
| Inventory Turnover Ratio (X) | 7.95 | 5.66 | 3.75 | 3.84 | 3.87 | |
| Dividend Payout Ratio (NP) (%) | 8.62 | 8.63 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 7.60 | 7.47 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 91.38 | 91.37 | 100.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 92.40 | 92.53 | 100.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,411.90 | 980.81 | 246.55 | 148.99 | 173.36 | |
| EV/Net Operating Revenue (X) | 5.95 | 3.11 | 1.28 | 0.96 | 1.12 | |
| EV/EBITDA (X) | 20.30 | 11.26 | 5.09 | -1.29 | -2.20 | |
| MarketCap/Net Operating Revenue (X) | 6.22 | 2.93 | 0.78 | 0.39 | 0.53 | |
| Retention Ratios (%) | 91.37 | 91.36 | 100.00 | 0.00 | 0.00 | |
| Price/BV (X) | 7.30 | 6.30 | 1.56 | -0.30 | -1.49 | |
| Price/Net Operating Revenue | 6.22 | 2.93 | 0.78 | 0.39 | 0.53 | |
| Earnings Yield | 0.03 | 0.06 | 0.26 | -2.98 | -2.63 |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth